Estramustine phosphate in the treatment of advanced malignant melanoma

R. Lopez, C. P. Karakousis, M. S. Didolkar, E. D. Holyoke

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Twenty-six patients (14 men and 12 women) with histologically proven advanced malignant melanoma, who previously had not responded to DTIC, methyl-CCNU, and procarbazine, received estramustine phosphate (Estracyt) (15 mg/m2) in daily divided doses. All patients had measurable disease. One patient developed a complete remission and one patient had improvement in liver function without measurable regression in the tumor. In 3 other patients (11%), the disease remained static for a period of 3-5 months. The mean survival time from the beginning of therapy was 16.8 months for the patients with a response or static disease and 2.18 months for those who had no response. Gastrointestinal toxicity was minimal; no hematologic toxicity was observed. It appears that estramustine phosphate used as a single agent for treating advanced malignant melanoma after patients failed to respond to DTIC and to the combination of methyl-CCNU and procarbazine has a poor response rate.

Original languageEnglish (US)
Pages (from-to)1329-1332
Number of pages4
JournalCancer treatment reports
Issue number9
StatePublished - 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Estramustine phosphate in the treatment of advanced malignant melanoma'. Together they form a unique fingerprint.

Cite this